Bausch Health has announced the launch of Ryaltris olopatadine / mometasone furoate nasal spray for in Canada. Bausch Health acquired the Canadian rights to Ryaltris from Glenmark in March 2021, and Health Canada approved the nasal spray for the treatment of moderate to severe seasonal allergic rhinitis in September 2022.
Ryaltris was approved by the FDA in January 2022 and launched in the US by Hikma in August of that year. The nasal spray has been approved in Australia since December 2019, in Russia since February 2021, and in much of Europe since April 2021.
Bausch Health Senior VP, Europe and Canada, Cees Heiman commented, “Bausch Health is very pleased that we are now able to make Ryaltris available to Canadians, providing an innovative new combination nasal spray treatment for SAR, which impacts the lives of the over 9 million Canadians who suffer from SAR or seasonal allergies often referred to as hay fever. The launch of this new therapy adds to our broad portfolio of treatments that further establishes Bausch Health as a trusted partner in the healthcare of Canadians.”
Read the Bausch Health Canada press release.
